UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Phase 2 study of the mTOR inhibitor everolimus in combination with bevacizumab in patients with sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors.

Participants in this research study have a tumor called malignant peripheral nerve sheath tumor (MPNST) which has not responded to treatment with one or more prior chemotherapy treatments and cannot be completely removed by surgery (unresectable), or has spread to other areas of the body (metastasized). The purpose of this study is to determine how well participants with MPNSTs respond (experience tumor shrinkage or lack of further tumor growth) to treatment with everolimus in combination with bevacizumab. Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. A maximum of 25 people will take part in this study nationwide.

Start Date
June 3, 2013
End Date
February 1, 2016
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Cindy Robertson 319-356-2778

bevacizumab ; cancer ; everolimus ; IRB# 201303715 ; malignant peripheral nerve sheath tumor (MPNST) ; phase II ; phase two ; SARC016 ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.